Accessibility Menu
Harvard Apparatus Regenerative Technology logo

Harvard Apparatus Regenerative Technology(OTC) HRGN

Market Cap$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-99%
5 Year-38%
1 Year-26%
1 Month-4%
$1.00
+0.00%
+0.00Today
Harvard Apparatus Regenerative Technology last closing stock price
MetricPriceDate
Last closeUSD 1.002026-08-04
Harvard Apparatus Regenerative Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.76%USD 1.052026-07-28
1 month-3.85%USD 1.042026-07-02
3 month-35.48%USD 1.552026-05-06
Year to date-45.65%USD 1.842025-12-31
1 year-26.47%USD 1.362025-08-04
3 year-75%USD 4.002023-08-01
5 year-37.5%USD 1.602021-08-05
Since inception-99.17%USD 120.002013-10-21

Harvard Apparatus Regenerative Technology Financials at a Glance

Market Cap

$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$445.00K

Net Income (TTM)

-$6.81M

EPS (TTM)

-$0.40

P/E Ratio

-2.48

Dividend

$0.00

Beta (Volatility)

-0.15 (Low)

Price

$1.00

Volume

106

Open

$1.00

Previous Close

$1.00

Daily Range

$1.00 - $1.00

52-Week Range

$0.96 - $2.22

Estimated Earnings Date

May 18, 2026

HRGN News

I'm Selling Harvard Apparatus Regenerative Technology

Jim RoyalNov 18, 2014

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology develops treatments for organ damage and disease. Its main focus is on esophageal implants and dietary supplements. These products help people with severe organ injuries or those seeking personal health support.

What’s on the Lab Table? (Products and Services)

  • Regenerative Biotech (0% revenue): Develops organ-regeneration therapies, mainly for severe esophageal disease, using patient-derived stem cells.
  • Cellspan Esophageal Implant (0% revenue): An implant designed to help patients with damaged esophagus tissue from cancer, trauma, or birth defects.
  • Consumer Health Products (100% revenue in 2025): Sells dietary supplements like CoQ-10, sleep aid gummies, and liver health products, mainly in Asia.
  • Global Distribution: Products sold through Health Regen, a distributor, with 96% of 2025 revenue from this channel.

Growth Spurts and Science Sprints (Growth and Expansion)

  • Launched exclusive global distribution with Health Regen in November 2024 for consumer health products.
  • Started phase 1 clinical trial for esophageal implant at Mayo Clinic, University of Michigan, and University of Southern California in 2025.
  • Partnered with Capital Institute of Pediatrics in Beijing for pediatric esophageal trials in 2025.
  • Introduced new dietary supplements, including CoQ-10 and sleep aid gummies, in 2025.
  • Changed company name from Biostage to Harvard Apparatus Regenerative Technology in July 2023.

Why This Company Isn’t Just Another Biotech

The company holds patents in the U.S. China, Japan, and Europe for organ-regeneration technology. It collaborates with major medical centers for clinical trials and product development. Its consumer health products reach global markets through a single distributor, focusing on Asia.

Five Things You Need to Know

  • Product revenue was $704,000 in 2025, up 64% from 2024.
  • All 2025 revenue came from consumer health products, not biotech therapies.
  • Net loss was $(6.9) million in 2025, improving 11% from 2024.
  • Cash on hand was $1.4 million at December 31, 2025, funding operations into Q2 2026.
  • Health Regen accounted for 96% of 2025 revenue and all accounts receivable.

Bottom Line

Harvard Apparatus Regenerative Technology has shifted from direct sales to a distributor model and expanded its clinical trial network. The company remains focused on developing organ-regeneration therapies while relying on consumer health products for current revenue.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Jun Li He, CFA, MBA

Website

hregen.com

Headquarters

Holliston, MA 01746, US

HRGN Financials

Key Financial Metrics (TTM)

Gross Margin

-84.04%

Operating Margin

-1689.21%

Net Income Margin

-1530.56%

Return on Equity

-786.49%

Return on Capital

-606.61%

Return on Assets

-378.81%

Earnings Yield

-40.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.58M

Volume

106

Avg. Volume

1.31K

Financials (TTM)

Gross Profit

-$374.00K

Operating Income

-$7.52M

EBITDA

-$6.70M

Operating Cash Flow

-$4.01M

Capital Expenditure

$0.00

Free Cash Flow

-$4.01M

Cash & ST Invst.

$419.00K

Total Debt

$173.00K

Harvard Apparatus Regenerative Technology Performance Analysis

Harvard Apparatus Regenerative Technology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 103,000N/A
20242024-12-31USD 430,000317.5%
20252025-12-31USD 704,00063.7%
Harvard Apparatus Regenerative Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-313.2%
Harvard Apparatus Regenerative Technology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.55-30.5%
20232023-12-31USD -0.6721.7%
20242024-12-31USD -0.52-22.0%
20252025-12-31USD -0.42-20.4%
Harvard Apparatus Regenerative Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-10.0%
Q32025-09-309.1%
Q42025-12-31-10.0%
Q12026-03-3117.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$226.00K

N/A

Gross Profit

$20.00K

+160.6%

Gross Margin

8.85%

N/A

Market Cap

$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.20M

N/A

Employees

8

N/A

Net Income

-$1.60M

+3.5%

EBITDA

-$1.57M

+8.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$419.00K

-75.8%

Total Debt

$173.00K

-36.4%

Accounts Receivable

$16.00K

+300.0%

Inventory

$15.00K

-68.8%

Long Term Debt

$55.00K

-68.0%

Short Term Debt

$118.00K

+18.0%

Return on Assets

-3.79%

N/A

Return on Invested Capital

-51.14%

N/A

Free Cash Flow

-$937.00K

-23.6%

Operating Cash Flow

-$937.00K

-23.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MVRBFMedivir AB (publ)
$0.82+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$108.27-0.14%
NVDANvidia
$219.22+0.03%
ONDSOndas
$8.87+0.00%
PATHUiPath
$13.82-0.02%

Questions About HRGN

What is the current price of Harvard Apparatus Regenerative Technology?

Harvard Apparatus Regenerative Technology is trading at $1.00 per share.

What is the 52-week range for Harvard Apparatus Regenerative Technology?

Over the past 52 weeks, Harvard Apparatus Regenerative Technology has traded between $0.96 and $2.22.

How much debt does Harvard Apparatus Regenerative Technology have?

As of the most recent reporting period, Harvard Apparatus Regenerative Technology reported total debt of $288.00K.

How much cash does Harvard Apparatus Regenerative Technology have on hand?

Harvard Apparatus Regenerative Technology reported $419.00K in cash and cash equivalents in its most recent financial results.

What is Harvard Apparatus Regenerative Technology’s dividend yield?

Harvard Apparatus Regenerative Technology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services